The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed,...read more
RxSight, which sells premium adjustable intraocular lenses used in cataract surgery, raised $118 million by offering 7.4 million shares at $16, the low end of the range of $16 to $18. RxSight markets its RxSight Light Adjustable Lens system, comprised of...read more
RxSight, a commercial-stage provider of post-cataract intraocular lens platform, announced terms for its IPO on Monday. The Aliso Viejo, CA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the...read more
After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million. Preclinical RNA biotech Transcode Therapeutics (RNAZ) priced at $4 to...read more
US IPO Weekly Recap: Biotechs pop and Robinhood flops in a record 20 IPO week
The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed,...read more
Intraocular lens platform RxSight prices IPO at $16 low end
RxSight, which sells premium adjustable intraocular lenses used in cataract surgery, raised $118 million by offering 7.4 million shares at $16, the low end of the range of $16 to $18. RxSight markets its RxSight Light Adjustable Lens system, comprised of...read more
Intraocular lens platform RxSight sets terms for $125 million IPO
RxSight, a commercial-stage provider of post-cataract intraocular lens platform, announced terms for its IPO on Monday. The Aliso Viejo, CA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the...read more
US IPO Weekly Recap: Micro-caps lead a quiet 2 IPO week
After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million. Preclinical RNA biotech Transcode Therapeutics (RNAZ) priced at $4 to...read more